Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
Naismith RT, Cohen JA, Bar-Or A, Comi G, Selmaj KW, Hartung HP, Sheffield JK, Krakovich A, Tatosian D, Cheng CY, Reardon J, Khaychuk V, Riolo JV, Silva D, Cree BA. Naismith RT, et al. Mult Scler. 2024 Feb;30(2):177-183. doi: 10.1177/13524585231216854. Epub 2023 Dec 21. Mult Scler. 2024. PMID: 38130041 Free PMC article.
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A. Derfuss T, et al. Among authors: bar or a. Ther Adv Neurol Disord. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39399100 Free PMC article.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Gold R, et al. N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287. N Engl J Med. 2012. PMID: 22992073 Free article. Clinical Trial.
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Miller DH, et al. Neurology. 2015 Mar 17;84(11):1145-52. doi: 10.1212/WNL.0000000000001360. Epub 2015 Feb 13. Neurology. 2015. PMID: 25681448 Free PMC article. Clinical Trial.
Incorporation of the central vein sign into the McDonald criteria.
Amin M, Nakamura K, Daboul L, O'Donnell C, Cao Q, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi PA, Cree BAC, Freeman L, Henry R, Longbrake EE, Oh J, Papinutto N, Pelletier D, Prčkovska V, Raza PC, Ramos M, Samudralwar R, Schindler M, Sotirchos ES, Sicotte N, Solomon AJ, Shinohara R, Reich DS, Sati P, Ontaneda D. Amin M, et al. Among authors: bar or a. Mult Scler Relat Disord. 2024 Nov 25;93:106182. doi: 10.1016/j.msard.2024.106182. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39622133
414 results